Olubukola Ayetiwa

Olubukola Ayetiwa is an associate in Goodwin’s Intellectual Property Litigation practice who focuses his practice on intellectual property and complex commercial matters on behalf of life sciences and technology companies. His practice includes representing clients in patent infringement, trade secret and trademark misappropriation, and licensing disputes.

Olubukola’s experience also includes representing life science companies in litigation under the Hatch Waxman Act.

Olubukola has experience in all phases of litigation. From pre-suit investigation through trial. Some of his recent experience includes:

• Represents Ossifi-Mab in patent infringement litigation involving Amgen’s osteoporosis drug, Evenity (Ossifi-Mab LLC v. Amgen, D. Mass.).
• Represented the University of Pittsburgh in a patent infringement and licensing dispute involving muscle-derived stem cell technology (University of Pittsburgh of the Commonwealth System of Higher Education v. Cook Myosite, Inc., W.D. Pa.).
• Represents Zealand Pharma in a trade secret dispute involving a peptide-based therapeutic for complement-mediated diseases (Amyndas Pharmaceuticals Single Member P.C. et al. v. Alexion Pharmaceuticals, Inc. et al., D. Mass.).
• Represented Two Harbors Investment Corporation in a complex, multi-faceted dispute involving breach of contract and trade secret misappropriation claims (PRCM Advisers LLC et al. v. Two Harbors Investment Corp., S.D.N.Y.).
• Represents an innovator pharmaceutical company in patent infringement litigation in the District of Delaware
• Represented generic pharmaceutical companies in Hatch-Waxman litigation in the District of New Jersey
• Defended a retail mortgage lender in trademark infringement litigation in the District of Arizona

Olubukola maintains an active pro bono practice, including representing clients in various immigration, constitutional, and civil rights matters. Olubukola worked with the ACLU of Ohio to file a lawsuit on behalf two transgender adolescents and their families, challenging Ohio’s House bill 68, a law passed in January 2024 that prohibits gender-affirming medical care.

Olubukola was a summer associate with Goodwin in 2021. Prior to joining Goodwin, Olubukola served as a judicial extern to the Hon. David J. Barron, Chief Judge of the U.S. Court of Appeals for the First Circuit, in 2021. Olubukola also completed an internship with Bristol-Myers Squibb in their Innovation Law – Patents Group in 2020.

Olubukola is a contributor to Goodwin’s PTAB Trial Tracker.